<DOC>
	<DOCNO>NCT01374360</DOCNO>
	<brief_summary>This study collection data evaluate safety characterize progression Paroxysmal Nocturnal Hemoglobinuria ( PNH ) .</brief_summary>
	<brief_title>Paroxysmal Nocturnal Hemoglobinuria ( PNH ) Registry</brief_title>
	<detailed_description>Collection data evaluate safety characterize progression Paroxysmal Nocturnal Hemoglobinuria ( PNH ) .</detailed_description>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Patients age , include minor , diagnosis PNH detect PNH clone , include patient previously treat Soliris withdrawn treatment . Patients minor must parent/legal guardian consent must willing able give assent , applicable determine Ethics Committees/Institutional Review Boards . Upon attain adulthood , patient must reconsented . Ability comprehend sign consent data enter PNH Registry . Inability unwillingness sign inform consent . Patients currently enrol interventional clinical trial treatment PNH enrol Registry time .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PNH</keyword>
	<keyword>Paroxysmal Nocturnal hemoglobinuria</keyword>
	<keyword>Soliris</keyword>
	<keyword>Eculizumab</keyword>
</DOC>